Südafrikanische Botschaft, Wien
Sandgasse 33, 1190 Wien, Österreich
Tel.: +43 1 320 6493
Fax: +43 1 320 6493 51
Notrufnummer +43 664 117 1801 -
NUR FÜR NOTFÄLLE
(NICHT FÜR VISUMSAUSKÜNFTE)

Besuchszeit Botschaft
Mo-Fr 08:00-12:45/13:30-16:30 Uhr
Besuchszeit Konsularabteilung

Visum, SA Citizen Services
Mo-Fr 08:30-12:00 Uhr

Topnews

26. März 2015

MEDIA RELEASE

FIRST-IN-AFRICA ISOTOPE-LABELLED THERANOSTIC PROCEDURE ON PROSTATE CANCER PATIENTS

Pretoria, 26 March 2015

Thursday, 26 March 2015, Steve Biko Academic Hospital and NTP Radioisotopes subsidiary of the South African Nuclear Energy Corporation in collaboration with ITG in Germany and AEC-Amersham has made provision for Professor Mike Sathekge to perform the first-in-Africa isotope-labelled theranostics procedure for prostate cancer on two patients.

NTP Group Managing Director, Ms Tina Eboka, said this has come together with the dedication of many who worked behind the scenes.  “NTP, its subsidiary company AEC-Amersham in association with ITG and Steve Biko Academic Hospital are proud of this milestone!  AEC-Amersham played a major role in ensuring the isotopes, peptides and sundry reagents necessary for the procedures, supplied by ITG, were timeously delivered to Professor M Sathekge at the Steve Biko Nuclear Medicine Department. NTP performed the labelling of the Prostate Specific Membrane Antigen (PSMA) together with an ITG representative who especially flew in from Germany.”

Professor Sathekge explained that Lutetium-177 (Lu-177) labelled (PSMA, a peptide) is used as the targeting (or tracer) medium and is very effective in detecting, staging and treating recurrent prostate cancer.  He said he believes that many prostate cancer patients will benefit from treatment with Lu-177 n.c.a added to carrier PSMA.  “Most prostate cases are often diagnosed at a late stage of the disease, so treatments must deal with a cancer, which may have spread to other parts of the body.”

Nuclear medicine specialists are excited about the potential of theranostics, a combination of therapy and diagnostics in which the same type of targeting molecule is used to obtain images and to deliver the therapeutic isotope dose, selectively, to the tumour site and to destroy cancerous cells.

In this procedure, PSMA is used as the targeting (or tracer) medium and is very effective in detecting, staging and treating recurrent prostate cancer. After performing a scan, the Lu-177 labelled PSMA is administered and transports the radioisotope selectively to the tumour(s), irradiating and killing the cancer cells and leaving healthy tissue unharmed. The full treatment involves a series of four intravenous injections, which are administered a month apart.  

Cancer of the prostate is the biggest carcinogenic killer, excluding skin cancers, of men in South Africa (16.3% of all cancer deaths and over 4 000 in number per year). Up to the age of 74, men have a 1 in 23 chance of developing prostate cancer and the rate is climbing as diagnosis improves and the population average age increases.

It is not yet known how many PSMA procedures will be in demand in South Africa but certainly it will be an appreciable number and will provide NTP with an additional weapon in the armoury that is progressively being assembled for fighting the scourge of cancer therefore bringing hope to many patients inflicted with prostate cancer in our country. 

About NTP Radioisotopes

NTP Radioisotopes SOC Ltd is a major player in the highly competitive radioisotopes industry worldwide.  A subsidiary of the South African Nuclear Energy Corporation (Necsa), NTP produces a quarter (10 million) of the world’s medical radioisotopes used to allow for about 40 million medical diagnostic images every year, making it the third largest producer and supplier globally. This proud South African corporate citizen is situated at the sophisticated Necsa nuclear facility site, west of Pretoria and routinely serves customers in 60 countries worldwide with its range of nuclear radiation-based products and services.  NTP employs ~275 employees, has maintained consistent revenue and market share growth and has over the past years created various business subsidiaries or increased holdings in these that strengthened its portfolio.

For more information on NTP Radioisotopes SOC Ltd visit: www.ntp.co.za

Media Contacts:

Xolisa Mabhongo

Necsa Group Executive: Corporate Services

 

Landline:  +27 12 305 4921

email: Xolisa.Mabhongo@necsa.co.za 

Elliot Mulane

Necsa: Manager Communication & Media Liaison

Landline:  +27 12 305 4427

mobile:  +27-78-803-5569

Email: elliot.mulane@necsa.co.za

 

 

 

 

Archiv

    Kategorieauswahl:

  • Wirtschaft
  • Tourismus
  • Südafrika
  • Internationale Beziehungen
  • Aussenpolitik
  • Südafrika in Österreich
  • Internationale Organisationen
  • Südafrika in Slowenien
  • Bilateral Relations
  • Presse
  • Topnews
  • Statements
 
© Copyright by SA Embassy 2020 | Impressum | Kontakt | Datenschutz | English